LIFEX RESEARCH PTE. LTD. (“The Company”) provides services related to new medical care including personalized/ regenerative medicine to customers as a business operator. The Company seeks to solve various problems such as “the medical expenses increasing issue” surrounding this business environment through utility-typed electronic token from “the combination technology of blockchain and Artificial Intelligence” point of view, and at the same time will raise funds for that.

By introducing this token system, the medical researchers and developers can receive the benefit of medical Big Data, and the token holder who is a participant of this service platform ecosystem can be rewarded the "incentives of new medical care services" in the future.

This utility-typed electronic token used for this service platform will be issued and operated using the Wowoo system which is the crypto currency issuing system.




Service provided by the operator

Business of LIFEX

LIFEX records and stores knowledge such as medical big data, its analysis results, results obtained from it in block chains, and provides useful information to stakeholders and commercial users. Medical big data can be used not only for development of specific medicines and preventive medicine by discovering common points such as diseases in the large universe, but also for regenerative medicine and personalized medicine.

Social Issues

As a social problem across the globe, there are:
•Increase in the medical expenses,
•and prolonged lives.

Our lives may be extended but may not be so healthy either. Needless to say, that everyone would rather live longer being healthy, that is without being conscious of your body of suffering.

Reference: World medical cost estimate

left: Population transition of the world / right: Relationship between GDP and medical expenditure

Reference: Trends in the size of medical products market in major countries


As a clue to solving these coming issues, Genetic information is becoming an important keyword.

Professor Yamanaka of Japan proposed, by introducing four factors (Oct3/4, Xox2, C-Myc, KIf4) into mouse embryonic fibroblasts, they were able to generate mouse induced pluripotent stem cell (iPS Cell: induced pluripotent stem cell) that had differentiation and pluripotent characteristics like that of ES cells (, of many possibilities that lie ahead. However, in reality, the technology for returning from human cells to iPS cells has not been firmly established, and we are still searching for the gene codes to be found which would return to each cell.

In order to manage our health in a more appropriate way, we must connect the needed information to establish medical treatments surrounding the gene and those people who are in need of them. Those institutions with this information must connect them to one. However, publishing information held by each research institution will also mean that they must give up their concessions. Then, the years, expenditures and expenses that they spent would not be rewarded. Also, even on the user side, the procedure for receiving new medical treatments properly would be very complicated and still needs to wait for the time to catch up.

Therefore, LIFEX uses blockchain technology to construct LIFEX BC Network that will connect researcher’s results fairly with people who are in need of gene therapy. Then, we would collect information on what kind of research and results has been made across the world in the iPS cell and therapeutic protein based on Vector virus technology, and allowing for hospitals, universities, and medical professionals to access to these information that are stocked within the LIFEX BC Network.

LIFEX Ecosystem Diagram
New medical care

Regenerative medicine is a medical regeneration of organs from iPS cells and is entering the stage of preclinical studies now. As an indispensable peripheral technology, there is a vector technology that transports iPS cells to RNA that proliferates cells outside the cell membrane while preventing the adverse effect of altering DNA of cell nucleus. In personalized medicine, genome analysis and omics analysis allow you to perform optimal medical care in accordance with individual differences in the effectiveness of treatment / medicine and side effects.

Patented technology

World patent for protein gene vector (technology provided by I’ROM Group)

We will be promoting this as a Vector DNA Research project.

Ultimately, general users can connect their health data and data at the hospital to this network, connect to the latest information on gene therapy, and if necessary receive advice from Artificial Intelligence of recommended therapy methods and facilities.


Medical Big data and AI

Of the medical big data, we can obtain conventional trial results that statistically process large scale population data for the development and preventive medicine of potent medicine effective for a certain disease. Processing with specific disease purpose / multiplayer data will be the center. Meanwhile, in personalized medicine, causal relationships of diseases and the like are determined based on genetic factors, acquired factors such as characteristics and lifestyle habits, various kinds of data such as anamnesis and injuries to individual patients, Discovery of optimal medical care, processing for specific individual purpose and various kinds of data will be the center. Artificial intelligence (AI) and high-speed arithmetic processing are indispensable in processing these medical big data.

In the inference by AI, there is a process of constructing a hypothesis model from less data such as preliminary estimation and a process of posteriori estimation that enhances the accuracy of the hypothesis model based on new data input one after another. Generally, there are algorithms such as a neural network and deep learning which restrict Boltzmann machine with preliminary estimation and back propagation by feedback of error such as back propagation to improve precision. Genetic algorithm etc. are famous for optimal search by AI.

By utilizing these AI techniques, it is possible to estimate the hypothesis model of how individual differences are occurring in personalized medicine, then input a large amount of various data of the individual to increase posterior estimation accuracy. The disease and its factors and the precision with respect to the disease can be improved and it is possible to derive the optimal treatment method and the optimal treatment facility etc. from the choices of various medical means. However, the computational algorithm of AI is progressing rapidly, so we always make use of the latest technology.

LIFEX will not limit on using particular artificial intelligence technology.

LIFEX will not limit on using particular artificial intelligence technology.

We will provide artificial intelligence API and a special format on the blockchain on the AI Chain, which will enable to analyze by connecting LIFEX BC Network to each available and appropriate Artificial intelligence. Using this AI Chain, LIFEX himself analyzes using artificial intelligence technology and requests analytical cooperation from artificial intelligence engineers around the world. For iPS cell research and therapeutic protein research, we are initially working with the research network based on the vector virus technology of I’ROM Group of Japan. I’ROM Group has already distributed their research kit to 100 locations around the world, so we plan to promote cooperation with these organizations.

In cooperation with LEGO (Life Intelligence Escrow Governance Organization) and Personal Data Security Assurance Organization, gene authentication technology is implemented in LIFEX BC Network as BC Biometrics. It is necessary to be based on genetic information in order to provide proper matching of health data and gene therapy data in a safe way.

Personal Attribute information (PAI) is decentralized and care is taken to enable authentication in a form that individuals cannot be identified. The institution connecting to this LIFEX BC Network will only be able to access the necessary information.

LIFEX BC Network

LIFEX BC Network has an API and SDK (development tool) for connecting to that information and exchanging information and providing hospitals, universities, medical staff, and private health service companies allowing access to information while allowing various services to be implemented.

Beneficiaries of this project

Beneficiaries of this project

The following stakeholders are expected to benefit from the deliverables of this project.

Data provider (Donor):

The desired data provider can register his genetic data, biometric data, medical record data, lifestyle habit data, etc. as a preparation for his future medical care. It can be an important guideline for receiving optimal medical care for himself as personalized medicine when suffering in the future, and in future iPS cells (artificial pluripotent stem cells) and animals. We are aiming to be able to receive regenerative medicine by ES cell (embryonic stem cell) origin. Unlike insurance which is monetary guarantee, this is convenience for self-treatment.

Medical institutions:

Medical institutions can carry out optimal treatment based on the data provided by donors and stored and their analysis results and referring to the knowledge accumulated by LIFEX. Not only the clinician but also the research doctor can receive data and knowledge on anonymous basis.

Medicine companies/Medical equipment companies:

The use as big data greatly contributes to the development department of pharmaceutical companies and medical equipment companies. The population at the clinical stage needs a huge number of monitor participants (clinical trial participants) to verify their effects and side effects. Medical big data stored on the block chain is authentic data that cannot be tampered with, and it can improve efficiency of the trial phase before regulatory approval. As a result, the cost reduction effect is reflected in the drug price, which will encourage environments where more patients can use new drugs at an appropriate reasonable price.

Supplemental Foods Companies:

Plant-derived and animal-derived health components provide a gradual effect, unlike chemicals. Verifying these effects is a difficult task even considering cost effectiveness and time required. Medical Big Data is useful for cohort studies that analyze incidence rates of populations exposed to specific factors and populations not exposed to them in analytical epidemiology and comparing incidence rates. Cohort study area that has long settled and has long settled in the past, such as race which intensively takes salt intake and not so, race which actively ingests specific natural foods, and race which is not so. Although it was difficult to find out, it is considered to be of great use to cohort research since it can save a lot of individual lifestyle habit data on the block chain.



LIFEX Council is an organization to review Token Sale issuing companies and projects on the Service Platform and to review the social nature of the project, and the Councilors are block chain engineers, proprietary technologies, founder, initial investment It consists of houses etc.

Yoshitake Awa
Yoshitake Awa
CEO / Lifex Research Pte. Ltd.
Winston Patrick Eric Koike
Winston Patrick Eric Koike
Fujimaru Nichols
CEO / Wowoo Pte. Ltd.
Yuya Sugiura
Marketing / Wowoo Pte. Ltd.
James MacWhyte
Tetsuya Oishi
Naohisa Yahagi
Keio University
Tsugumine Shu
President / ID Pharma Co., Ltd.
Adam Vaziri
Founder and CEO of QRC HK
Toyotaka Mori
CEO / I’ROM Group
Masatsune Okajima
Vice President / MediciNova, Inc
Takayuki Nakamura CEO / OKEIOS Co., Ltd.



Token Name LIFEX
Token Symbol LFX
Payments Accepted NEO **NEP-5 address shall be required
Hard Cap 444,444,444 LFX
Soft Cap 311,111,111 LFX
Total Token Supply 2,222,222,222 LFX


Token Sale 20%
Reserve & Inventory 30%
Marketing expenses 5%
Operations 5%
Founders etc 40%


Q4 2018
Vector DNA Research Phase1.0
LIFEX BC Network Ver1.0
AI Chain Ver1.0
BC Biometrics Ver1.0
Q2 2019
iPS cells Collect research results
Q3 2019
Vector DNA Research Phase2.0
LIFEX BC Network Ver2.0
AI Chain Ver2.0
BC Biometrics Ver2.0
Q1 2020
Therapeutic protein Collect research results
Q2 2020
iPS cells Collect research results
Q3 2020
Vector DNA Research Phase3.0
LIFEX BC Network Ver3.0
AI Chain Ver3.0
BC Biometrics Ver3.0
Q1 2021
Therapeutic protein Collect research results
Q2 2021
Vector DNA Research Phase4.0
LIFEX BC Network Ver4.0
AI Chain Ver4.0
BC Biometrics Ver4.0